Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin and Etoposide

Withdrawn before enrolling

Conditions studied: Small Cell Lung Cancer

In brief

This pilot research trial studies molecular signatures of the return of cancer after a period of improvement (relapse) in tissue samples from patients with small cell lung cancer who are receiving or planning to receive cisplatin and etoposide. Studying samples of tissue from patients with small cell lung cancer in the laboratory may help doctors learn more about the changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer relapse.

Key facts

Study ID

NCT02250404

Run by

University of Southern California

People needed

0

Starts

2014-08-22

Expected to finish

2019-08-22

Last updated by the study team

2018-05-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any patient seen at Norris or County with histologically confirmed SCLC, with tissue in the Norris Cancer Center Tumor Repository
• Patients must be undergoing or about to start first line treatment with cisplatin and etoposide
• Patients may not have a second malignancy

Where it is running

• Los Angeles County-USC Medical Center — Los Angeles, California, United States
• USC Norris Comprehensive Cancer Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.